[go: up one dir, main page]

FR2998799B1 - USE OF MICROORGANISMS TO DECREASE TRIMETHYLAMINE RATE IN INTESTINES, TREATMENT OF TRIMETHYLAMINUREMIA AND PREVENTION OF ATHEROMIC PLATE FORMATION - Google Patents

USE OF MICROORGANISMS TO DECREASE TRIMETHYLAMINE RATE IN INTESTINES, TREATMENT OF TRIMETHYLAMINUREMIA AND PREVENTION OF ATHEROMIC PLATE FORMATION

Info

Publication number
FR2998799B1
FR2998799B1 FR1261507A FR1261507A FR2998799B1 FR 2998799 B1 FR2998799 B1 FR 2998799B1 FR 1261507 A FR1261507 A FR 1261507A FR 1261507 A FR1261507 A FR 1261507A FR 2998799 B1 FR2998799 B1 FR 2998799B1
Authority
FR
France
Prior art keywords
trimethylaminuremia
decrease
trimethylamine
tma
atheromic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR1261507A
Other languages
French (fr)
Other versions
FR2998799A1 (en
Inventor
Jean-Francois Brugere
Guillaume Borrel
Paul William O'toole
Corinne Malpuech-Brugere
Monique Alric
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universite Clermont Auvergne
Original Assignee
Universite Clermont Auvergne
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universite Clermont Auvergne filed Critical Universite Clermont Auvergne
Priority to FR1261507A priority Critical patent/FR2998799B1/en
Priority to CA2893265A priority patent/CA2893265A1/en
Priority to CN201380069004.9A priority patent/CN104918633A/en
Priority to US14/648,186 priority patent/US10238695B2/en
Priority to EP13766995.8A priority patent/EP2925346A1/en
Priority to PCT/EP2013/070249 priority patent/WO2014082773A1/en
Publication of FR2998799A1 publication Critical patent/FR2998799A1/en
Application granted granted Critical
Publication of FR2998799B1 publication Critical patent/FR2998799B1/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Composition contenant un microorganisme, de préférence une Archaea, exprimant une TMA méthyltransférase et une protéine corrinoïde acceptrice de groupement méthyle de TMA, capable de métaboliser la triméthylamine (TMA) en présence d'hydrogène dans l'intestin, pour utilisation comme médicament pour traiter diminuer ou supprimer la TMA au niveau intestinal et dans le foie. Cette composition est utile pour traiter la triméthylaminurémie, diminuer le taux de TMAO plasmatique, prévenir la formation de plaques d'athérome et/ou prévenir les maladies cardiovasculaires.Composition containing a microorganism, preferably an Archaea, expressing a TMA methyltransferase and a corrinoid acceptor protein of a methyl group of TMA, capable of metabolizing trimethylamine (TMA) in the presence of hydrogen in the intestine, for use as a medicament for treating decrease or suppress TMA in the intestine and in the liver. This composition is useful for treating trimethylaminuremia, lowering the level of TMAO in plasma, preventing the formation of atheromatous plaques and / or preventing cardiovascular disease.

FR1261507A 2012-11-30 2012-11-30 USE OF MICROORGANISMS TO DECREASE TRIMETHYLAMINE RATE IN INTESTINES, TREATMENT OF TRIMETHYLAMINUREMIA AND PREVENTION OF ATHEROMIC PLATE FORMATION Expired - Fee Related FR2998799B1 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
FR1261507A FR2998799B1 (en) 2012-11-30 2012-11-30 USE OF MICROORGANISMS TO DECREASE TRIMETHYLAMINE RATE IN INTESTINES, TREATMENT OF TRIMETHYLAMINUREMIA AND PREVENTION OF ATHEROMIC PLATE FORMATION
CA2893265A CA2893265A1 (en) 2012-11-30 2013-09-27 Use of microorganisms for reducing the level of trimethylamine in a human body cavity in particular for the treatment of trimethylaminuria or of bacterial vaginosis and the prevention of cardiovascular diseases
CN201380069004.9A CN104918633A (en) 2012-11-30 2013-09-27 Use of microorganisms for reducing the level of trimethylamine in a human body cavity, in particular for the treatment of trimethylaminuria or of bacterial vaginosis and the prevention of cardiovascular diseases
US14/648,186 US10238695B2 (en) 2012-11-30 2013-09-27 Use of microorganisms for reducing the level of trimethylamine in a human body cavity, in particular for the treatment of trimethylaminuria or of bacterial vaginosis and the prevention of cardiovascular diseases
EP13766995.8A EP2925346A1 (en) 2012-11-30 2013-09-27 Use of microorganisms for reducing the level of trimethylamine in a human body cavity, in particular for the treatment of trimethylaminuria or of bacterial vaginosis and the prevention of cardiovascular diseases
PCT/EP2013/070249 WO2014082773A1 (en) 2012-11-30 2013-09-27 Use of microorganisms for reducing the level of trimethylamine in a human body cavity, in particular for the treatment of trimethylaminuria or of bacterial vaginosis and the prevention of cardiovascular diseases

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1261507A FR2998799B1 (en) 2012-11-30 2012-11-30 USE OF MICROORGANISMS TO DECREASE TRIMETHYLAMINE RATE IN INTESTINES, TREATMENT OF TRIMETHYLAMINUREMIA AND PREVENTION OF ATHEROMIC PLATE FORMATION

Publications (2)

Publication Number Publication Date
FR2998799A1 FR2998799A1 (en) 2014-06-06
FR2998799B1 true FR2998799B1 (en) 2015-09-04

Family

ID=47741094

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1261507A Expired - Fee Related FR2998799B1 (en) 2012-11-30 2012-11-30 USE OF MICROORGANISMS TO DECREASE TRIMETHYLAMINE RATE IN INTESTINES, TREATMENT OF TRIMETHYLAMINUREMIA AND PREVENTION OF ATHEROMIC PLATE FORMATION

Country Status (1)

Country Link
FR (1) FR2998799B1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111693687B (en) * 2020-05-28 2021-09-17 长沙都正生物科技股份有限公司 Preparation method of biological negative sample and biological standard substance and TMAO detection method

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4115340A1 (en) * 1991-05-10 1992-11-12 Forschungszentrum Juelich Gmbh MICROBIOLOGICALLY PREPARED TRIMETHYLAMINE DEHYDROGENASE, METHOD FOR THEIR OBTAINMENT AND ITS USE
CA2790371C (en) * 2009-05-28 2020-09-01 The Cleveland Clinic Foundation Trimethylamine-containing compounds for diagnosis and prediction of disease

Also Published As

Publication number Publication date
FR2998799A1 (en) 2014-06-06

Similar Documents

Publication Publication Date Title
Sun et al. Therapeutic manipulation of gut microbiota by polysaccharides of Wolfiporia cocos reveals the contribution of the gut fungi-induced PGE2 to alcoholic hepatic steatosis
Ohtani et al. Gut‐liver axis‐mediated mechanism of liver cancer: a special focus on the role of gut microbiota
Kim et al. Mucin degrader Akkermansia muciniphila accelerates intestinal stem cell-mediated epithelial development
Vernier et al. Estrogen-related receptors are targetable ROS sensors
Liu et al. AMPK: a balancer of the renin–angiotensin system
Wang et al. Akkermansia supplementation reverses the tumor-promoting effect of the fecal microbiota transplantation in ovarian cancer
Jackson et al. Plasmalogen biosynthesis by anaerobic bacteria: identification of a two-gene operon responsible for plasmalogen production in Clostridium perfringens
Janes et al. EphA3 biology and cancer
Chang et al. 4-Acetylantroquinonol B inhibits colorectal cancer tumorigenesis and suppresses cancer stem-like phenotype
Zhong et al. Emerging molecular basis of hematogenous metastasis in gastric cancer
UA113530C2 (en) Lactic acid extraction
Baffy Gut microbiota and cancer of the host: colliding interests
MA38099B1 (en) New compounds triazolopyrazines substituted brd4 inhibitors
Zhao et al. Inhibition of cell proliferation and induction of autophagy by KDM2B/FBXL10 knockdown in gastric cancer cells
Holvoet Stress in obesity and associated metabolic and cardiovascular disorders
Chen et al. Regulatory role of miR-125a/b in the suppression by selenium of cadmium-induced apoptosis via the mitochondrial pathway in LLC-PK1 cells
Heng et al. Identification of choline-degrading bacteria from healthy human feces and used for screening of trimethylamine (TMA)-lyase inhibitors
Sun et al. Dual oxidases participate in the regulation of hemolymph microbiota homeostasis in mud crab Scylla paramamosain
Vanichapol et al. Secretory High‐Mobility Group Box 1 protein affects regulatory T cell differentiation in neuroblastoma microenvironment in vitro
de Souza et al. Celecoxib and ibuprofen restore the ATP content and the gluconeogenesis activity in the liver of walker-256 tumor-bearing rats
FR2998799B1 (en) USE OF MICROORGANISMS TO DECREASE TRIMETHYLAMINE RATE IN INTESTINES, TREATMENT OF TRIMETHYLAMINUREMIA AND PREVENTION OF ATHEROMIC PLATE FORMATION
Wang et al. Crosstalk between microbial biofilms in the gastrointestinal tract and chronic mucosa diseases
Zhang et al. Inactivation of semicarbazide-sensitive amine oxidase induces the phenotypic switch of smooth muscle cells and aggravates the development of atherosclerotic lesions
TW200745059A (en) Sulfonyl-substituted bicyclic compounds as modulators of PPAR
Li et al. Ampicillin exacerbates acetaminophen‐induced acute liver injury by inducing intestinal microbiota imbalance and butyrate reduction

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 4

PLFP Fee payment

Year of fee payment: 5

PLFP Fee payment

Year of fee payment: 6

PLFP Fee payment

Year of fee payment: 7

PLFP Fee payment

Year of fee payment: 8

PLFP Fee payment

Year of fee payment: 9

PLFP Fee payment

Year of fee payment: 10

ST Notification of lapse

Effective date: 20230705